Syndax Pharmaceuticals In... (SNDX)
Syndax Pharmaceuticals Statistics
Share Statistics
Syndax Pharmaceuticals has 86.02M shares outstanding. The number of shares has increased by 1.22% in one year.
| Shares Outstanding | 86.02M |
| Shares Change (YoY) | 1.22% |
| Shares Change (QoQ) | 0.78% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 84.15M |
| Failed to Deliver (FTD) Shares | 2 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 22.38M, so 26.22% of the outstanding shares have been sold short.
| Short Interest | 22.38M |
| Short % of Shares Out | 26.22% |
| Short % of Float | 27.6% |
| Short Ratio (days to cover) | 8.36 |
Valuation Ratios
The PE ratio is -3.54 and the forward PE ratio is -3.8. Syndax Pharmaceuticals's PEG ratio is -0.14.
| PE Ratio | -3.54 |
| Forward PE | -3.8 |
| PS Ratio | 47.7 |
| Forward PS | 1.8 |
| PB Ratio | 3.92 |
| P/FCF Ratio | -4.11 |
| PEG Ratio | -0.14 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Syndax Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.82, with a Debt / Equity ratio of 0.04.
| Current Ratio | 5.82 |
| Quick Ratio | 5.82 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.04 |
| Interest Coverage | -68.91 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $87.7K |
| Profits Per Employee | $-1.18M |
| Employee Count | 270 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 2.26 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -45.57% in the last 52 weeks. The beta is 0.92, so Syndax Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.92 |
| 52-Week Price Change | -45.57% |
| 50-Day Moving Average | 14.21 |
| 200-Day Moving Average | 17.44 |
| Relative Strength Index (RSI) | 45.26 |
| Average Volume (20 Days) | 2.12M |
Income Statement
In the last 12 months, Syndax Pharmaceuticals had revenue of 23.68M and earned -318.76M in profits. Earnings per share was -3.73.
| Revenue | 23.68M |
| Gross Profit | 22.85M |
| Operating Income | -339.67M |
| Net Income | -318.76M |
| EBITDA | -313.82M |
| EBIT | -313.83M |
| Earnings Per Share (EPS) | -3.73 |
Balance Sheet
The company has 154.08M in cash and 12.12M in debt, giving a net cash position of 141.97M.
| Cash & Cash Equivalents | 154.08M |
| Total Debt | 12.12M |
| Net Cash | 141.97M |
| Retained Earnings | -1.22B |
| Total Assets | 724.82M |
| Working Capital | 499.51M |
Cash Flow
In the last 12 months, operating cash flow was -274.9M and capital expenditures 0, giving a free cash flow of -274.9M.
| Operating Cash Flow | -274.9M |
| Capital Expenditures | 0 |
| Free Cash Flow | -274.9M |
| FCF Per Share | -3.22 |
Margins
Gross margin is 96.51%, with operating and profit margins of -1434.43% and -1346.11%.
| Gross Margin | 96.51% |
| Operating Margin | -1434.43% |
| Pretax Margin | -1346.11% |
| Profit Margin | -1346.11% |
| EBITDA Margin | -1325.26% |
| EBIT Margin | -1434.43% |
| FCF Margin | -1160.91% |
Dividends & Yields
SNDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for SNDX is $37, which is 185.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $37 |
| Price Target Difference | 185.7% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | -1.56 |
| Piotroski F-Score | 3 |